Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.

Kevin P MarescaJianqing ChenDivya MathurAnand GiddabasappaAdam RootJatin NarulaLindsay KingDavid SchaerJonathan GolasKeith KobylarzEdward RosfjordEdmund KeliherLaigao ChenSripad RamEve H PickeringJames S HardwickPaul A RejtoAmira HusseinOhad IlovichKevin StatonIan WilsonTimothy J McCarthy

Published in: Molecular imaging and biology (2021)

Immune-imaging technologies for quantitative cellular measures would be a valuable biomarker in immunotherapeutic clinical development. We demonstrated a qualification of 89Zr-IAB22M2C PET to evaluate PD responses (mice) to a novel immunotherapeutic.

Keyphrases

pet imaging
high resolution
computed tomography
positron emission tomography
mass spectrometry
skeletal muscle
mesenchymal stem cells
fluorescence imaging
wild type
nk cells